Jan
16
2020
On demand

A pragmatic approach to the buy vs build manufacturing dilemma

The decision to outsource manufacturing or produce a therapeutic product in house plagues many biopharmaceutical executives. Each decision requires a careful assessment of multiple variables such as timelines,IP protection, forecast, capital allocation, technical capabilities, and market strategy. Every situation is unique and typically requires compromises and often results in valuable lessons learned.We will present a case study of one economic assessment of a buy versus build decision model. The panel will discuss other scenarios to generate a useful discussion of the possible options and the potential outcomes.

Attendees will learn:

  • Financial modeling of buy vs build scenarios
  • Considerations when manufacturing at a CMO
  • Benefits of outsourcing or insourcing
  • In-house manufacturing options for retrofitting existing structure, stick-built or modular builds
  • Technical challenges when manufacturing gene therapies

Nacim Haderbache
Commercial Strategy Leader at Cytiva
Carol Houts
Director, Regulatory & Quality at Germfree Laboratories
Joseph Phillips
Senior Vice President & Head of Pharmaceutical Development at ARMAGEN, INC.

SPEAKERS

Nacim Haderbache
Commercial Strategy Leader at Cytiva
Carol Houts
Director, Regulatory & Quality at Germfree Laboratories
Joseph Phillips
Senior Vice President & Head of Pharmaceutical Development at ARMAGEN, INC.

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
34
Days
22
Hrs
53
Min
Register

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
6
Hrs
53
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
26
Days
22
Hrs
53
Min
Register

Taking a right first-time approach to optimize end-to-end viral vector...

H Lesch
J Depollier
Hanna Lesch
Hanna Lesch
Chief Technology Officer at Exothera
Julien Depollier
Julien Depollier
Business Director, Americas at Polyplus-transfection
9 Jun 2022
21
Days
22
Hrs
53
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
19
Days
22
Hrs
53
Min
Register